A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy

Trial Profile

A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms PANORAMA
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 02 May 2016 Status changed from not yet recruiting to recruiting.
    • 29 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top